TCF-001 TRACK (Target Rare Cancer Knowledge) Study

Part of paid clinical trials in Cambridge, Massachusetts.

Sponsor
TargetCancer Foundation
Study ID
NCT04504604
Status
Recruiting
Apply to this trial

Conditions

  • Cancer of Unknown Primary Site
  • Cholangiocarcinoma
  • Rare Cancers

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • FoundationOne CDx and FoundationOne Liquid CDx — DIAGNOSTIC_TEST
    Eligible patients will have Foundation Medicine blood and tissue testing and have their results reviewed by the study's Virtual Molecular Tumor Board which, in turn, will make recommendations for treatment to treating physicians.

Study Details

This open label, non-randomized, multi-center, pragmatic study aims to establish whether patients with rare tumors can benefit from matched molecular therapy as dictated by their next-generation sequencing (NGS) results.

Key Dates

Start date
Oct 1, 2020
Status verified
May 2026
Primary completion
Sep 30, 2028
Completion
Dec 31, 2028

Study Design

Enrollment
400 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
DIAGNOSTIC

Arms

  • Active Comparator: Cholangiocarcinoma
    Eligible patients that present with Cholangiocarcinoma.
  • Active Comparator: Cancer of Unknown Primary (CUP)
    Eligible patients with cancer of unknown primary site (CUP).
  • Active Comparator: Other remaining rare cancers (solid tumors & lymphomas)
    Eligible patients that meet the definition of rare cancers (incidence of less than 6 per 100,000 in the United States).

Primary Outcome Measure

Percent of participants who receive a molecularly targeted matched treatment after recommendation from the VMTB. [ Time Frame: 2 years ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
TargetCancer FoundationCambridgeMassachusetts02139
Mary Oster
[email protected]
617-299-0389
Shumei Kato, M.D (PRINCIPAL_INVESTIGATOR)

Find similar trials in Cambridge, MA

By research site
TargetCancer Foundation· Cambridge, MA

Related Studies